Enhancing therapeutic outcomes with artificial intelligence for HR-positive, HER2-negative metastatic breast cancer - PubMed
3 months ago
- #CDK4/6 Inhibitors
- #Metastatic Breast Cancer
- #Artificial Intelligence
- CDK4/6 inhibitors are a first-line treatment for HR-positive metastatic breast cancer, but resistance develops.
- Fan et al. report results from the LINUX trial, a phase 2 study using AI digital pathology to guide therapy post-CDK4/6i progression.
- The study highlights the potential of AI in improving therapeutic outcomes for resistant cases.
- Conflict of interest disclosures include consulting and research support from major pharmaceutical companies for the authors.